High-dose glucocorticoid before hip and knee arthroplasty:To use or not to use-that's the question by Kehlet, Henrik & Lindberg-Larsen, Viktoria
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
High-dose glucocorticoid before hip and knee arthroplasty
Kehlet, Henrik; Lindberg-Larsen, Viktoria
Published in:
Acta Orthopaedica
DOI:
10.1080/17453674.2018.1475177
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Citation for published version (APA):
Kehlet, H., & Lindberg-Larsen, V. (2018). High-dose glucocorticoid before hip and knee arthroplasty: To use or
not to use-that's the question. Acta Orthopaedica, 89(5), 477-479.
https://doi.org/10.1080/17453674.2018.1475177
Download date: 03. Feb. 2020
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=iort20
Acta Orthopaedica
ISSN: 1745-3674 (Print) 1745-3682 (Online) Journal homepage: https://www.tandfonline.com/loi/iort20
High-dose glucocorticoid before hip and knee
arthroplasty: To use or not to use—that’s the
question
Henrik Kehlet & Viktoria Lindberg-Larsen
To cite this article: Henrik Kehlet & Viktoria Lindberg-Larsen (2018) High-dose glucocorticoid
before hip and knee arthroplasty: To use or not to use—that’s the question, Acta Orthopaedica,
89:5, 477-479, DOI: 10.1080/17453674.2018.1475177
To link to this article:  https://doi.org/10.1080/17453674.2018.1475177
© 2018 The Author(s). Published by Taylor &
Francis on behalf of the Nordic Orthopedic
Federation.
Published online: 21 May 2018.
Submit your article to this journal 
Article views: 970
View Crossmark data
Citing articles: 1 View citing articles 
Acta Orthopaedica 2018; 89 (5): 477–479 477
Annotation
High-dose glucocorticoid before hip and knee arthroplasty: 
To use or not to use—that’s the question
© 2018 The Author(s). Published by Taylor & Francis on behalf of the Nordic Orthopedic Federation. This is an Open Access article distributed under the terms 
of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by/4.0)
DOI 10.1080/17453674.2018.1475177
During the last decade, “fast-track” or “enhanced recovery” 
programs have been introduced in hip and knee arthroplasty 
(THA/TKA) with a continuing improvement in recovery and 
consequently reduction in length of stay (LOS) (Zhu et al. 
2017). Importantly, LOS may depend on early organ dysfunc-
tion, appearance of complications, or organizational factors. 
Early postoperative organ dysfunction including pain, ortho-
static intolerance, cardiovascular and thromboembolic mor-
bidity, cognitive disturbances, nausea and vomiting, sleep dis-
turbances, fatigue, and loss of muscle function may all depend 
on factors involved in the global surgical stress response. Two 
main mechanisms include the neuro-endocrine responses and 
the inflammatory-immunological responses, where the latter 
may be most important to determine post THA/TKA recov-
ery (Gaudilliere et al. 2014). Of the various pharmacological 
interventions to reduce the inflammatory responses, glucocor-
ticoids are the most powerful (de la Motte et al. 2014, Stein-
thorsdottir et al. 2017, Toner et al. 2017). Notably, systemic 
perioperative glucocorticoid administration has been the sub-
ject of 7 systematic reviews and/or meta-analyses in THA/
TKA since December 2016, summarizing that glucocorticoids 
may reduce nausea and vomiting as well as acute early post-
operative pain. Interestingly, all of the 7 reviews (Hartman et 
al. 2017, Li et al. 2017, Liu et al. 2017, Meng and Li 2017, Yue 
et al. 2017, Li et al. 2018, Mohammad et al. 2018) claim to 
be the first and even more interestingly they include between 
4 and 14 studies, thereby questioning the search methodol-
ogy. Although all reviews agree that additional glucocorticoid 
may provide more analgesia, a critical assessment of efficacy 
was not done in relation to basic anesthetic/analgesic princi-
ples with different regimes in the different RCTs and a dose-
finding analysis was only discussed in one review, but was 
not possible (Yue et al. 2017). Overall, most pain studies have 
used a limited dose of glucocorticoid (about 6–12 mg dexa-
methasone), but the most detailed studies discussed below 
have used a higher dose (125 mg methylprednisolone/~ 25 
mg dexamethasone). Nevertheless, a more critical update on 
the use of perioperative glucocorticoid in THA and TKA may 
be appropriate in the light of more recent findings of specific 
pathophysiological responses to surgery and safety aspects.
Surgical pathophysiology
The anti-inflammatory effects of high-dose systemic gluco-
corticoid are well documented by reduced responses in IL-6 
and CRP (Yue et al. 2017). Consequently, there seems to be 
less postoperative fatigue (Lunn et al. 2011, 2013), which may 
provide an excellent start to postoperative recovery combined 
with the documented analgesic and anti-nausea and vomiting 
effects. Recently, other interesting effects on postoperative 
THA/TKA responses have shown that the usual degradation 
of endothelial barrier function after TKA was attenuated by 
preoperative high-dose (125 mg) methylprednisolone (~ 25 
mg dexamethasone) (Lindberg-Larsen et al. 2017b) while 
there was no effect on the usual early (48 h) pronounced loss 
of quadriceps function (Lindberg-Larsen et al. 2017a), despite 
an inhibition of the inflammatory response. In addition, the 
endogenous anti-inflammatory protein pentraxin-3 (PTX-3) 
was significantly increased by preoperative high-dose gluco-
corticoids (Lindberg-Larsen et al. 2018b), although the clini-
cal consequences regarding a potential reduction of infectious 
complications remain to be studied. The conventional effect of 
glucocorticoid on glucose homeostasis has also been assessed 
in a recent very detailed study on the different components 
of glucose homeostasis (hyperglycemia, insulin resistance, 
C-peptide response) and showed a transient impairment in 
glucose homeostasis lasting for only about 24–48 hours after 
125 mg preoperative methylprednisolone (Lindberg-Larsen 
et al. 2018a). The surgery-induced increased thrombogenic 
responses may also be attenuated by perioperative high-dose 
glucocorticoid (Yue et al. 2017), although the potential positive 
effects on thromboembolic complications (Li et al. 2018) need 
further evaluation. Other aspects of early postoperative recov-
ery after THA and TKA such as sleep disturbances (Krenk et 
al. 2012), and early cognitive dysfunction (Krenk et al. 2014) 
have not been elucidated so far. Interestingly, in one RCT, 125 
mg methylprednisolone reduced early fatigue despite subjec-
tive reports on sleep quality on the first night being reduced 
(Lunn et al. 2011). With regard to early mobilization, preop-
erative 125 mg methylprednisolone did not improve ortho-
static intolerance after THA despite a reduced inflammatory 
response (Lindberg-Larsen et al. 2018c). Finally, the patho-
physiological effects of perioperative high-dose glucocorti-
coid on the early recovery phase from the operating theatre to 
the postoperative recovery unit (PACU) and discharge to the 
ward may potentially shorten the PACU stay due to improved 
opioid-sparing analgesia and PONV reduction, but calls for 
future detailed PACU discharge criteria studies (Steinthors-
dottir et al. 2017).
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In summary, preoperative high-dose glucocorticoid may 
attenuate some, but not all undesirable pathophysiological 
responses to surgery. Consequently, detailed dose-finding 
studies and whether repeat dosing may further enhance recov-
ery is required, as few and inconclusive data are available. 
Finally, the delicate balance between necessary and undesir-
able inflammatory response needs attention, since an inflam-
matory response is required for wound healing etc., but an 
exaggerated response may delay recovery (Gaudilliere et al. 
2014).
Safety aspects
Overall, there seem to be no safety issues in using a high-
dose of glucocorticoid perioperatively in the surgical literature 
(Toner et al. 2017). However, due to the small-scale RCTs in 
THA/TKA (Hartman et al. 2017, Li et al. 2017, Liu et al. 2017, 
Meng and Li 2017, Yue et al. 2017, Li et al. 2018, Mohammad 
et al. 2018), there was no final conclusion with regard to safety 
aspects. More recently, a large prospective comparative mul-
ticenter cohort study in TKA was analyzed including about 
1,500 consecutive patients after introduction of high-dose glu-
cocorticoid vs. about 2,400 patients in the period before (Jør-
gensen et al. 2017). These high-volume data showed no risk 
signals from using a high dose (125 mg methyl prednisolone) 
regarding different types of medical complications or super-
ficial wound or deep infections. However, no conclusive data 
are available from insulin-dependent diabetics (Lindberg-
Larsen et al. 2018a) and no safety studies are available evalu-
ating higher doses or repeat dosing or consequences on pros-
thesis fixation. Based upon all 7 systematic reviews, no risk of 
glucocorticoid-induced psychosis has been reported.
Future strategies and conclusions
Due to the increased interest in short-stay and outpatient 
THA and TKA (Vehmeijer et al. 2018), and given the above-
mentioned efficacy and safety aspects, the question is whether 
perioperative high-dose glucocorticoid may further enhance 
early recovery and facilitate a safe outpatient setup. A recent 
study in unselected patients in the Danish government-run 
healthcare system (Gromov et al. 2017), and including pre-
operative 125 mg methylprednisolone in addition to standard 
multimodal analgesia, showed that for about 15% of patients 
undergoing THA and TKA this could be performed in an out-
patient setting. However, the most interesting finding from that 
study was the question why the remaining 85% of patients did 
not recover early, again emphasizing the many early recovery 
problems mentioned in the introduction of our article. Thus, the 
major future challenge that remains to be answered is whether 
an individualized and potentially higher dose of glucocorti-
coid with more pronounced anti-inflammatory effects can be 
safe and further enhance early recovery and reduce organ dys-
function in these 85% of patients. Interestingly, a large safety 
non-RCT cohort study (Jørgensen et al. 2017) showed that the 
proportion of patients staying > 4 days was reduced by 50% 
by high-dose glucocorticoid. Also, future studies should focus 
on specific “high-risk” pain responders like pain catastrophiz-
ers, preoperative opioid users, etc. (Gilron et al. 2018) Finally, 
it remains to be evaluated whether the recovery benefits are 
correlated with the magnitude of reduction in the inflamma-
tory responses or whether the approach should be used only in 
certain “high-inflammatory” responders.
In conclusion, the previous and the more recent data suggest 
several major beneficial recovery effects of the anti-inflamma-
tory effects of perioperative high-dose glucocorticoid in THA 
and TKA and so far without safety issues. Consequently, it 
may at this time be appropriate to recommend its use on a 
“routine” basis at least in TKA, but calling for more data from 
specific “risk” groups (THA, high-pain responders, diabet-
ics, infected revisions, etc.) although the optimal dose needs 
to be defined. Perioperative use of high doses of glucocorti-
coids may therefore represent a further step to enhance recov-
ery after “fast-track” or “enhanced recovery” THA and TKA 
(Kehlet 2013).
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